These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8759889)

  • 1. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload.
    Jensen PD; Heickendorff L; Pedersen B; Bendix-Hansen K; Jensen FT; Christensen T; Boesen AM; Ellegaard J
    Br J Haematol; 1996 Aug; 94(2):288-99. PubMed ID: 8759889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron overload in patients with myelodysplastic syndromes.
    Jensen PD
    Curr Hematol Malig Rep; 2007 Feb; 2(1):13-21. PubMed ID: 20425384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron overload in myelodysplastic syndromes (MDS).
    Gattermann N
    Int J Hematol; 2018 Jan; 107(1):55-63. PubMed ID: 29177643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of iron overload in adults with continuous parenteral desferrioxamine.
    Cooper B; Bunn HF; Propper RD; Nathan DG; Rosenthal DS; Moloney WC
    Am J Med; 1977 Dec; 63(6):958-66. PubMed ID: 605917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of transfusional iron overload before and during iron chelation by magnetic resonance imaging of the liver and determination of serum ferritin in adult non-thalassaemic patients.
    Jensen PD; Jensen FT; Christensen T; Ellegaard J
    Br J Haematol; 1995 Apr; 89(4):880-9. PubMed ID: 7772526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
    Maurillo L; Breccia M; Buccisano F; Voso MT; Niscola P; Trapè G; Tatarelli C; D'Addosio A; Latagliata R; Fenu S; Piccioni AL; Fragasso A; Aloe Spiriti MA; Refrigeri M; Criscuolo M; Musto P; Venditti A
    Eur J Haematol; 2015 Jul; 95(1):52-6. PubMed ID: 25764148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic computed tomography for monitoring the iron status of haemodialysis patients with haemosiderosis treated with recombinant human erythropoietin.
    De Marchi S; Cecchin E
    Clin Sci (Lond); 1991 Jul; 81(1):113-21. PubMed ID: 1649718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron overload in myelodysplastic syndromes.
    Mahesh S; Ginzburg Y; Verma A
    Leuk Lymphoma; 2008 Mar; 49(3):427-38. PubMed ID: 18297518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
    Imran F; Phatak P
    Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine.
    Hoffbrand AV; Gorman A; Laulicht M; Garidi M; Economidou J; Georgipoulou P; Hussain MA; Flynn DM
    Lancet; 1979 May; 1(8123):947-9. PubMed ID: 87616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desferrioxamine-chelatable iron (DCI), a component of serum non-transferrin-bound iron (NTBI) used for assessing iron chelation therapy.
    Breuer W; Ermers MJ; Pootrakul P; Abramov A; Hershko C; Cabantchik ZI
    Transfus Sci; 2000 Dec; 23(3):241-2. PubMed ID: 11099901
    [No Abstract]   [Full Text] [Related]  

  • 12. [Iron chelation therapy and its influence on the alleviation of EPO resistance in MDS patients].
    Zhang Y; Xiao C; Gu SC; Chang CK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1027-32. PubMed ID: 25130822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
    Remacha AF; Arrizabalaga B; Del Cañizo C; Sanz G; Villegas A
    Ann Hematol; 2010 Feb; 89(2):147-54. PubMed ID: 19690857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload.
    Du Y; Long Z; Chen M; Han B; Hou B; Feng F
    Acta Haematol; 2017; 138(2):119-128. PubMed ID: 28866669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.
    Metzgeroth G; Dinter D; Schultheis B; Dorn-Beineke A; Lutz K; Leismann O; Hehlmann R; Hastka J
    Ann Hematol; 2009 Apr; 88(4):301-10. PubMed ID: 18758781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload.
    Schafer AI; Rabinowe S; Le Boff MS; Bridges K; Cheron RG; Dluhy R
    Arch Intern Med; 1985 Jul; 145(7):1217-21. PubMed ID: 3925909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
    Shah J; Kurtin SE; Arnold L; Lindroos-Kolqvist P; Tinsley S
    Clin J Oncol Nurs; 2012 Jun; 16 Suppl():37-46. PubMed ID: 22641283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.
    Messa E; Cilloni D; Messa F; Arruga F; Roetto A; Saglio G
    Acta Haematol; 2008; 120(2):70-4. PubMed ID: 18827475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
    Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human erythropoietin in the treatment of myelodysplastic syndromes--response patterns.
    Lewinski UH; Floru S; Cohen AM; Mittelmann M
    Leuk Lymphoma; 1994 Sep; 15(1-2):149-52. PubMed ID: 7858493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.